Brinker Capital’s Sarepta Therapeutics SRPT Stock Holding History

Brinker Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$669K	Sell	4,173 -345	-8%	-$46.9K	0.02%	626
2020 Q1	$442K	Sell	4,518 -29	-0.6%	-$3.31K	0.02%	677
2019 Q4	$587K	Buy	4,547 +1,683	+59%	+$170K	0.02%	670
2019 Q3	$216K	Buy	2,864 +197	+7%	+$23.3K	0.01%	901
2019 Q2	$405K	Buy	2,667 +370	+16%	+$45K	0.01%	731
2019 Q1	$274K	Buy	+2,297	New	+$295K	0.01%	820
2018 Q3	–	Sell	-2,277	Closed	-$301K	–	1013
2018 Q2	$301K	Buy	+2,277	New	+$215K	0.01%	862
2018 Q1	–	Sell	-4,034	Closed	-$224K	–	1023
2017 Q4	$224K	Buy	+4,034	New	+$214K	0.01%	926

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Brinker Capital's SRPT Position: Q2 2020 in Review

Brinker Capital reduced its Sarepta Therapeutics (SRPT) stake by 7.6% in Q2 2020, selling an estimated $46.9K and leaving 4,173 shares worth $669K. The position accounts for 0.02% of the portfolio, ranked #626.

Brinker Capital first reported a position in SRPT in Q4 2017 and has held it in 8 quarters since. 409 funds tracked by Wall St. Rank hold SRPT as of Q2 2020.

Brinker Capital held 4,173 shares of Sarepta Therapeutics worth $669K as of Q2 2020.
Brinker Capital sold 345 Sarepta Therapeutics shares in Q2 2020, an estimated $46.9K.
Sarepta Therapeutics made up 0.02% of Brinker Capital's portfolio in Q2 2020, its #626 holding.
Brinker Capital first reported a position in Sarepta Therapeutics in Q4 2017 and has held it in 8 quarters since.
409 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2020.

Based on Brinker Capital's 13F filing for Q2 2020, filed 30 Jul 2020.